Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.

× No keyword cloud information.

20 in total

1. Chemotherapeutics in the treatment of multiple sclerosis.

Authors: Bernd C Kieseier; Douglas R Jeffery
Journal: Ther Adv Neurol Disord Date: 2010-09 Impact factor: 6.570

2. [Current immunotherapy of multiple sclerosis].

Authors: F Paul; K Ruprecht
Journal: Nervenarzt Date: 2015-08 Impact factor: 1.214

Review 3. A critical appraisal of treatment decisions in multiple sclerosis--old versus new.

Authors: Bernd C Kieseier; Olaf Stüve
Journal: Nat Rev Neurol Date: 2011-04-05 Impact factor: 42.937

4. [Therapeutic options for autoimmune encephalomyelitis].

Authors: N Borisow; H Prüss; F Paul
Journal: Nervenarzt Date: 2013-04 Impact factor: 1.214

Review 5. [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Authors: L Klotz; A Berthele; W Brück; A Chan; P Flachenecker; R Gold; A Haghikia; K Hellwig; B Hemmer; R Hohlfeld; T Korn; T Kümpfel; M Lang; V Limmroth; R A Linker; U Meier; S G Meuth; F Paul; A Salmen; M Stangel; B Tackenberg; H Tumani; C Warnke; M S Weber; T Ziemssen; F Zipp; H Wiendl
Journal: Nervenarzt Date: 2016-06 Impact factor: 1.214

10. Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?

Authors: Anja Mähler; Silvia Mandel; Mario Lorenz; Urs Ruegg; Erich E Wanker; Michael Boschmann; Friedemann Paul
Journal: EPMA J Date: 2013-02-18 Impact factor: 6.543

Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.

1. Chemotherapeutics in the treatment of multiple sclerosis.

2. [Current immunotherapy of multiple sclerosis].

Review 3. A critical appraisal of treatment decisions in multiple sclerosis--old versus new.

4. [Therapeutic options for autoimmune encephalomyelitis].

Review 5. [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Review 6. Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.

Review 7. Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Review 8. An integrated approach to design novel therapeutic interventions for demyelinating disorders.

Review 9. Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

10. Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?